CRGX

Cargo Therapeutics, Inc. (CRGX)

Market Open
10 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
4. 60
0
0%
$
211.2M Market Cap
- P/E Ratio
0% Div Yield
1,335,226 Volume
- Eps
$ 4.6
Previous Close
Day Range
4.57 4.62
Year Range
3 25.45
Want to track CRGX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 32 days
An Investigation Has Been Launched Into CARGO Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

An Investigation Has Been Launched Into CARGO Therapeutics, Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESS Newswire / February 28, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Accessnewswire | 4 months ago
CRGX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by CARGO Therapeutics, Inc.

CRGX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by CARGO Therapeutics, Inc.

NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.

Accessnewswire | 4 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CARGO Therapeutics, Inc - CRGX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CARGO Therapeutics, Inc - CRGX

NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("Cargo" or the "Company") (NASDAQ:CRGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Accessnewswire | 4 months ago
Levi & Korsinsky Reminds Shareholders of an Investigation into CARGO Therapeutics, Inc. (CRGX) Regarding Potential Securities Fraud Allegations

Levi & Korsinsky Reminds Shareholders of an Investigation into CARGO Therapeutics, Inc. (CRGX) Regarding Potential Securities Fraud Allegations

NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.

Accessnewswire | 4 months ago
The Schall Law Firm Invites Shareholders With Losses In CARGO Therapeutics, Inc. To Join A Securities Fraud Investigation

The Schall Law Firm Invites Shareholders With Losses In CARGO Therapeutics, Inc. To Join A Securities Fraud Investigation

LOS ANGELES, CA / ACCESS Newswire / February 27, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Accessnewswire | 4 months ago
CARGO Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - CRGX

CARGO Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - CRGX

NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.

Accessnewswire | 4 months ago
CARGO Therapeutics, Inc. Being Investigated on Behalf of CARGO Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details.

CARGO Therapeutics, Inc. Being Investigated on Behalf of CARGO Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details.

NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.

Accessnewswire | 4 months ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CARGO Therapeutics, Inc - CRGX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CARGO Therapeutics, Inc - CRGX

NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("Cargo" or the "Company") (NASDAQ: CRGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Prnewswire | 4 months ago
Levi & Korsinsky Reminds CARGO Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - CRGX

Levi & Korsinsky Reminds CARGO Therapeutics, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - CRGX

NEW YORK, NY / ACCESS Newswire / February 25, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.

Accessnewswire | 4 months ago
The Schall Law Firm Invites Shareholders With Losses In CARGO Therapeutics, Inc. To Join A Securities Fraud Investigation

The Schall Law Firm Invites Shareholders With Losses In CARGO Therapeutics, Inc. To Join A Securities Fraud Investigation

LOS ANGELES, CA / ACCESS Newswire / February 25, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of CARGO Therapeutics, Inc. ("CARGO" or "the Company") (NASDAQ:CRGX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Accessnewswire | 4 months ago
CRGX ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of CARGO Therapeutics, Inc. Shareholders Who Lost Money

CRGX ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of CARGO Therapeutics, Inc. Shareholders Who Lost Money

NEW YORK, NY / ACCESS Newswire / February 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.

Accessnewswire | 4 months ago
CRGX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by CARGO Therapeutics, Inc.

CRGX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by CARGO Therapeutics, Inc.

NEW YORK, NY / ACCESS Newswire / February 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.

Accessnewswire | 4 months ago
Loading...
Load More